05.02.24 -- Listen now: Precision Drug Delivery, Clinical Trial Progress for Parkinson's, Funding Alzheimer's Tx, and more.

Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead-engineered hematopoietic cell (eHSC) product candidate. Dr. Ang is back to talk about how Vor has treated 8 patients demonstrating clinical proof of concept and is also in the clinic with a CAR-T that could be used in combination with shielded stem cell transplants.

BlueRock Therapeutics' SVP head of development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months.

Check out this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since this episode was recorded, Karen's thoughtful perspective on the sometimes tumultuous Alzheimer's therapeutics space is valuable to any drug developer working in the cognitive medicines arena.

Ampersand Biomedicines CEO Jason Gardner, Ph.D. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with the Flagship Pioneering-backed Ampersand, he's putting all those hard-fought lessons to good use.

Dr. Bobby Reddy, Chief Medical Officer at ImmunityBio, gives us a long look behind the curtain at the commercial preparations the company is making as its lead Phase 3 candidate, Anktiva, nears the goal line in non-muscle invasive bladder cancer (NMIBC). 

Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Dr. Kakkar’s worldview is shaped by his work as a physician — work he continues at Brigham and Women’s Hospital even as he builds Tome Biosciences, where he serves as President & CEO.